New Treatment Options for Patients with Metastatic Prostate Cancer: What Is the Optimal Sequence?

Joyce M. Van Dodewaard-De Jong, Henk M.W. Verheul, Haiko J. Bloemendal, John M.H. De Klerk, Michael A. Carducci, Alfons J.M. Van Den Eertwegh

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.

Original languageEnglish (US)
Pages (from-to)271-279
Number of pages9
JournalClinical Genitourinary Cancer
Issue number4
StatePublished - Aug 1 2015


  • Chemotherapy
  • Hormonal therapy
  • Immunotherapy
  • Prostate cancer
  • Radiopharmaceuticals

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'New Treatment Options for Patients with Metastatic Prostate Cancer: What Is the Optimal Sequence?'. Together they form a unique fingerprint.

Cite this